---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-027960"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2024-03-29T23:59:59+00:00"
generated_at: "2026-06-04T05:26:08.750682+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# INmune Bio reports FY2023 net loss of $30.0M; pipeline updates for XPro, INKmune

## Summary
- Net loss for FY2023 was $30.0M, up from $27.3M in FY2022; R&D spend rose to $20.3M.
- Cash and equivalents at Dec 31, 2023: $35.8M; shares outstanding ~18.0M as of Mar 28, 2024.
- XPro AD02 Alzheimer's trial on track for mid-2024 enrollment completion; top-line data ~6 months later.
- Phase I/II INKmune mCRPC trial enrolled first patient Dec 2023; cohort 2 to open after DSMC review in mid-April.
- Company winding down AML program to focus on prostate cancer and other solid tumors.

## SEC filing metadata
- accession: 0001213900-24-027960
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2024-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390024027960/0001213900-24-027960-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390024027960/ea0202918-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-027960
- JSON: https://secwatch.observer/filing/0001213900-24-027960.json
- Plain text: https://secwatch.observer/filing/0001213900-24-027960.txt

## Key facts
- Earnings Releases
  Inmune Bio, Inc. reported the year ended December 31, 2023 results: net income approximately $30.0 million.
  - Period: the year ended December 31, 2023
  - Net income: approximately $30.0 million
  - Result: reported results
  source text: Net loss attributable to common stockholders for the year ended December 31, 2023, was approximately $30.0 million, compared to approximately $27.3 million during the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711754/000121390024027960/0001213900-24-027960-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.